Helixgate

Helixgate

Uncategorized

STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got more earnings today, and my colleague Drew Joseph brings us a dispatch from Rome.

The need-to-know this morning

  • German drug maker Bayer said it is acquiring Perfusion Therapeutics, a privately held developer of treatments for eye diseases. 
  • Vivek Ramaswamy, the biotech executive-turned politician, won the Republican primary for governor of Ohio on Tuesday. 
  • Madrigal Pharma said sales of its MASH drug Rezdiffra were $311 million in the first quarter, topping Wall Street estimates. 
  • United Therapeutics also reported earnings

Novo Nordisk saw its shares rise after being able to report some less-bad news.

The Danish firm, which had been trailing rival Eli Lilly in the obesity drug market, has gained some recent momentum with the hugely successful launch of its Wegovy pill in the U.S. And in releasing first quarter results Wednesday, Novo ticked up its guidance for the year, saying that adjusted sales will drop from 4% to 12% (the company previously said they would be down 5% to 13%), an identical shift also seen in its forecast for adjusted operating profit. The improving outlook is largely driven by better sales performance, Novo said.

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got more earnings today, and my colleague Drew Joseph brings us a dispatch from Rome.

The need-to-know this morning

  • German drug maker Bayer said it is acquiring Perfusion Therapeutics, a privately held developer of treatments for eye diseases. 
  • Vivek Ramaswamy, the biotech executive-turned politician, won the Republican primary for governor of Ohio on Tuesday. 
  • Madrigal Pharma said sales of its MASH drug Rezdiffra were $311 million in the first quarter, topping Wall Street estimates. 
  • United Therapeutics also reported earnings

Novo Nordisk saw its shares rise after being able to report some less-bad news.

The Danish firm, which had been trailing rival Eli Lilly in the obesity drug market, has gained some recent momentum with the hugely successful launch of its Wegovy pill in the U.S. And in releasing first quarter results Wednesday, Novo ticked up its guidance for the year, saying that adjusted sales will drop from 4% to 12% (the company previously said they would be down 5% to 13%), an identical shift also seen in its forecast for adjusted operating profit. The improving outlook is largely driven by better sales performance, Novo said.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Amgen, Sanofi commit nearly $600M to North American expansions

Published

on

Sanofi’s investment will support a Canadian site’s efforts to apply AI to drug production, while Amgen has unveiled the second expansion of its Puerto Rico plant in quick succession.

Continue Reading

Uncategorized

Novo hikes guidance on Wegovy pill’s fast sales start

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

Read More

Published

on

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

Read More

Continue Reading

Uncategorized

CoCoGraph AI Model Generates Molecules that Comply with Rules of Chemistry

Published

on

Developing new molecular compounds is crucial to address pressing challenges, from drug discovery to sustainable materials. However, discovering viable new molecules is challenging due to the vastness of the search space. 

In a new paper published in Nature Machine Intelligence titled, “A collaborative constrained graph diffusion model for the generation of realistic synthetic molecules,” researchers from Universitat Rovira i Virgili (URV) have developed an AI tool capable of generating molecules that are guaranteed to comply with the rules of chemistry. The model, named CoCoGraph, operates similarly to generative AI tools for text or images, such as ChatGPT or Dall-E.  

“These models create new content that looks very much like the real thing. Our algorithm does the same, but with molecules,” said Roger Guimerà, PhD, ICREA research professor in the department of chemical engineering at URV and co-corresponding author of the study. He explains that the number of possible chemical molecules could be up to 10⁶⁰ variants, which is more than the number of water molecules in the ocean.  

CoCoGraph uses a diffusion model, a technique common in image generation, which progressively “disorders” a real molecule and trains the system to learn how to reconstruct it. 

Marta Sales-Pardo, PhD, professor in the department of chemical engineering at URV and co-corresponding author of the study, explains that the model begins with a real molecule, breaks the bonds, and then creates new bonds at random. The model then learns to reverse this process to reconstruct coherent structures. 

Notably, CoCoGraph directly incorporates the basic rules of chemistry, such as maintaining the correct number of bonds, to guarantee that generated molecules are chemically valid. The system is also more efficient, uses fewer parameters, and requires less computing power to generate molecules more quickly. 

The research team has compared the performance of CoCoGraph with other state-of-the-art models and analyzed 36 physicochemical properties, such as solubility and structural complexity. For two-thirds of these properties, the CoCoGraph generated molecules are chemically more realistic than those from other models. 

Although the model cannot yet design molecules with a specific function, researchers have identified molecules with properties similar to the drug, paracetamol. They have also explored techniques to partially modify an existing molecule to create new variants with similar characteristics, which are useful for optimizing drugs or developing new materials. 

The next step is to design molecules with specific properties, such as solubility and low toxicity. If successful, the technology could accelerate the discovery of new solutions across pharmacology and materials science in a chemical universe that is still practically unexplored. 

The post CoCoGraph AI Model Generates Molecules that Comply with Rules of Chemistry appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Advertisement

Trending